Zobrazeno 1 - 10
of 83
pro vyhledávání: '"FALUYI, O."'
Autor:
Primrose, JN, Fox, RP, Morement, H, Chan, O, Rees, C, Ma, YT, Hickish, T, Falk, S, Finch-Jones, M, Pope, I, Corrie, P, Crosby, T, Sothi, S, Sharkland, K, Adamson, D, Wall, L, Evans, J, Dent, J, Hombaiah, U, Iwuji, C, Anthoney, A, Bridgewater, J, Cunningham, D, Gillmore, R, Ross, P, Slater, S, Wasan, H, Waters, J, Valle, JW, Palmer, D, Malik, H, Neoptolemos, J, Faluyi, O, Sumpter, K, Dernedde, U, Maduhusudan, S, Cogill, G, Archer, C, Iveson, T, Wadsley, J, Darby, S, Peterson, M, Mukhtar, AA, Thorpe, JG, Bateman, A, Tsang, D, Cummins, S, Nolan, L, Beaumont, E, Prasad, R, Mirza, D, Stocken, D, Praseedom, R, Davidson, B, Raftery, J, Zhu, S, Garden, J, Stubbs, C, Coxon, F, Primrose, John N, Fox, Richard P, Palmer, Daniel H, Malik, Hassan Z, Prasad, Raj, Mirza, Darius, Anthony, Alan, Corrie, Pippa, Falk, Stephen, Finch-Jones, Meg, Wasan, Harpreet, Ross, Paul, Wall, Lucy, Wadsley, Jonathan, Evans, Jeff T R, Stocken, Deborah, Praseedom, Raaj, Ma, Yuk Ting, Davidson, Brian, Neoptolemos, John P, Iveson, Tim, Raftery, James, Zhu, Shihua, Cunningham, David, Garden, O James, Stubbs, Clive, Valle, Juan W, Bridgewater, John
Publikováno v:
In The Lancet Oncology May 2019 20(5):663-673
Autor:
Edeline, J., Blanc, J.-F., Campillo-Gimenez, B., Ma, Y.-T., King, J., Faluyi, O., Mathurin, J., Ghazi, S., Palmer, D.H., Meyer, T.
Publikováno v:
In European Journal of Cancer November 2017 86:135-142
Autor:
OBAZELU, P. A., FALUYI, O.
Publikováno v:
Journal of Applied Sciences & Environmental Management; Dec2023, Vol. 27 Issue 12, p2845-2852, 8p
Publikováno v:
Clinical & Experimental Immunology. Jan2018, Vol. 191 Issue 1, p32-41. 11p.
Autor:
McNamara, M. G., Bridgewater, J., Palmer, D.H., Faluyi, O., Wasan, H., Patel, A., Ryder, W.D., Barber, S., Gnanaranjan, C., Ghazaly, E., Evans, T.R.J, Valle, J.W.
Background:\ud Cisplatin/gemcitabine is standard first‐line treatment for patients with advanced biliary tract cancer (ABC). NUC‐1031 (phosphoramidate transformation of gemcitabine) is designed to enhance efficacy by maximizing intratumoral activ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::ca21f38f46a758c29253ad44fad20e18
https://eprints.gla.ac.uk/225871/1/225871.pdf
https://eprints.gla.ac.uk/225871/1/225871.pdf
Autor:
Faluyi, O. B.1 faluyi2005@yahoo.com, Agbede, J. O.1
Publikováno v:
Archiva Zootechnica. 2017, Vol. 20 Issue 1, p65-75. 11p.
Autor:
Faluyi, O. B.1 faluyi2005@yahoo.com, Adekolurejo, O.1
Publikováno v:
Archiva Zootechnica. 2016, Vol. 19 Issue 1, p57-68. 12p.
Publikováno v:
Archiva Zootechnica. 2014, Vol. 17 Issue 2, p27-39. 13p.
Autor:
Neoptolemos, J.P., Palmer, D.H., Ghaneh, P., Psarelli, E.E., Valle, J.W., Halloran, C.M., Faluyi, O., O'Reilly, D.A., Cunningham, D., Wadsley, J., Darby, S., Meyer, T., Gillmore, R., Anthoney, A., Lind, P., Glimelius, B., Falk, S., Izbicki, J.R., Middleton, G.W., Cummins, S., Ross, P.J., Wasan, H., McDonald, A., Crosby, T., Ma, Y.T., Patel, K., Sherriff, D., Soomal, R., Borg, D., Sothi, S., Hammel, P., Hackert, T., Jackson, R., Büchler, M.W., European Study Group for Pancreatic Cancer
BACKGROUND: The ESPAC-3 trial showed that adjuvant gemcitabine is the standard of care based on similar survival to and less toxicity than adjuvant 5-fluorouracil/folinic acid in patients with resected pancreatic cancer. Other clinical trials have sh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::1ec5e6e466b47b4a92503f735b35583d
https://eprints.whiterose.ac.uk/114332/1/1-s2.0-S0140673616324096-main.pdf
https://eprints.whiterose.ac.uk/114332/1/1-s2.0-S0140673616324096-main.pdf
Publikováno v:
Archiva Zootechnica; 2020, Vol. 23 Issue 1, p22-33, 12p